EyeGate Pharmaceuticals to Present at BIO CEO & Investor Conference in New York City
January 29, 2019 06:55 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced that the Company will attend and present at the 21st BIO...
EyeGate Pharmaceuticals Announces Meeting Date with FDA
January 16, 2019 06:55 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 16, 2019 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today confirmed that it is scheduled to meet with the U.S. Food and Drug...
EyeGate Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
November 13, 2018 16:05 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced financial results for the three-month period ended...
EyeGate Pharma Announces Positive Results in Second PRK Study
November 13, 2018 06:55 ET
|
EyeGate Pharmaceuticals, Inc.
Data confirms results from earlier study WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced top-line data from its study evaluating the...
EyeGate Pharma Announces Positive Results in Punctate Epitheliopathy Study
November 13, 2018 06:55 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced top-line data from its study evaluating the potential of EyeGate’s Ocular Bandage Gel...
EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care
October 02, 2018 06:55 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Oct. 02, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules
September 25, 2018 06:55 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
EyeGate Pharmaceuticals Completes Enrollment in Both PRK and PE Pilot Studies
September 24, 2018 06:55 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
EyeGate Announces Randomization of First Patients in Study for Punctate Epitheliopathies
September 04, 2018 08:31 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
EyeGate Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis
September 04, 2018 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...